Furthermore, it is widely believed that female TP53 mutation carriers could benefit from breast cancer surveillance similarly to BRCA1/2 mutation carriers, yet using non-irradiating surveillance such as MRI and ultrasound [24]. This evidence concerns the gene BRCA1 and breast cancer.